Stockhub

Blueprint Medicines Corporation: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

19 August 2022

12 August 2022

5 August 2022

  • curprev 00:1100:11, 5 August 2022‎ Paris talk contribs‎ 1,625 bytes +1,625‎ Created page with "Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Blueprint_Medicines_Corporation’